Phase II study of a radiotherapy total dose increase in hypoxic lesions identified by 18F-misonidazole PET/CT in patients with non–small cell lung carcinoma (RTEP5 …
…, N Aide, S Danhier, F Denis, JP Muratet… - Journal of Nuclear …, 2017 - Soc Nuclear Med
See an invited perspective on this article on page 1043 . This multicenter phase II study
investigated a selective radiotherapy dose increase to tumor areas with significant 18 F-…
investigated a selective radiotherapy dose increase to tumor areas with significant 18 F-…
[PDF][PDF] Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma
JP Muratet, A Daver, JF Minier… - Journal of Nuclear …, 1998 - Soc Nuclear Med
I11 or 37 MBq 13119 days before the administration of a therapeutic dose of 3.7 GBq I3t1@
To assess treatment efficacy, all patients were studied with@ II 6.0 — 16.8 mo later. …
To assess treatment efficacy, all patients were studied with@ II 6.0 — 16.8 mo later. …
[HTML][HTML] Challenges and caveats of a multi-center retrospective radiomics study: an example of early treatment response assessment for NSCLC patients using FDG …
…, W van Elmpt, D de Ruysscher, JP Muratet… - PloS one, 2019 - journals.plos.org
Background Prognostic models based on individual patient characteristics can improve
treatment decisions and outcome in the future. In many (radiomic) studies, small size and …
treatment decisions and outcome in the future. In many (radiomic) studies, small size and …
Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer
MO Bernier, O Morel, P Rodien, JP Muratet… - European journal of …, 2005 - Springer
Purpose The aim of this study was to assess the prognostic factors for treatment efficacy,
and in particular the increase in serum thyroglobulin (Tg) level at the time of the first ablative …
and in particular the increase in serum thyroglobulin (Tg) level at the time of the first ablative …
Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma
JP Muratet, P Giraud, A Daver… - The Journal of Nuclear …, 1997 - search.proquest.com
Treatment in Differentiated Thyroid Carcinoma Page 1 Predicting the Efficacy of First Iodine—131
Treatment in Differentiated Thyroid Carcinoma Jean-Pierre Muratet. Philippe Giraud, Alain …
Treatment in Differentiated Thyroid Carcinoma Jean-Pierre Muratet. Philippe Giraud, Alain …
Early assessment of metabolic response by 18F-FDG PET during concomitant radiochemotherapy of non–small cell lung carcinoma is associated with survival: a …
S Yossi, S Krhili, JP Muratet, AL Septans… - Clinical nuclear …, 2015 - journals.lww.com
Background and Purpose We performed a retrospective single-center study to assess if
midtreatment 18 F-FDG PET/CT could predict local control and survival in patients with locally …
midtreatment 18 F-FDG PET/CT could predict local control and survival in patients with locally …
Use of metabolic parameters as prognostic factors during concomitant chemoradiotherapy for locally advanced cervical cancer
S Krhili, JP Muratet, S Roche, Y Pointreau… - American journal of …, 2017 - journals.lww.com
Objectives: To investigate the use of metabolic parameters as early prognostic factors during
concomitant chemoradiotherapy for locally advanced cervix carcinoma (LACC). Materials …
concomitant chemoradiotherapy for locally advanced cervix carcinoma (LACC). Materials …
Positron emission tomography (PET) and [F-18]-fluorodeoxyglucose (FDG)
…, JP Vuillez, JN Talbot, J LUMBROSCO, JP Muratet… - Bulletin du cancer, 1998 - jle.com
2. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic
trapping as a principle of radiopharmaceutical design: some factors responsible for the …
trapping as a principle of radiopharmaceutical design: some factors responsible for the …
Abnormal iodine-131 uptake in a benign mucinous ovarian cystadenoma mimicking struma ovarii
O Morel, V Rohmer, S Girault, JP Muratet… - Clinical Nuclear …, 2007 - journals.lww.com
A 37-year-old woman was referred for ablative radioiodine treatment 5 months after total
thyroidectomy for pT1N1Mx papillary thyroid carcinoma. After thyroid hormone treatment …
thyroidectomy for pT1N1Mx papillary thyroid carcinoma. After thyroid hormone treatment …
False-positive suspicion of a thyroid metastatic lesion by In-111 pentetreotide uptake in a toxic nodular goiter
…, ANNM SULTAN, P Giraud, JP Muratet… - Clinical Nuclear …, 2001 - journals.lww.com
Sarcoidosis is a chronic granulomatous disease involving multiple organs. Symptomatic
diffuse muscle involvement is rare, occurring in only 0.5% to 1.4% of cases. The authors report …
diffuse muscle involvement is rare, occurring in only 0.5% to 1.4% of cases. The authors report …